Business Context and Reporting Period
Company: PRO-DEX, INC. (PDEX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended March 31, 2025 (Fiscal Q3 2025)
Business Overview: Pro-Dex designs, develops, and manufactures autoclavable, battery-powered, and electric surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets. The company also manufactures rotary air motors. Operations are based in Irvine and Tustin, California.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Mar 31, 2025 | 9 Months Ended Mar 31, 2025 | 9 Months Ended Mar 31, 2024 |
|---|---|---|---|
| Net Sales | $17,414 | $49,099 | $38,819 |
| Gross Profit | $5,798 | $16,019 | $10,462 |
| Gross Margin | 33.3% | 32.6% | 27.0% |
| Operating Income | $3,640 | $9,345 | $4,822 |
| Net Income | $3,275 | $7,781 | $540 |
| Diluted EPS | $0.98 | $2.31 | $0.15 |
| Cash and Equivalents (Mar 31, 2025) | $4,473 | ||
| Total Debt (Notes Payable) | $18,329 | ||
| Working Capital | $31,626 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22% ($3.1M) for the quarter and 27% ($10.3M) for the nine-month period compared to the prior year. Growth was driven by medical device product sales (+22% QoQ, +28% YoY) and repair revenue (+15% QoQ, +29% YoY).
- Profitability: Net income surged to $3.3M for the quarter and $7.8M for the nine-month period, compared to $0.7M and $0.5M in the prior year periods. This was significantly aided by a $595k gain on the sale of investments and a $1.1M unrealized gain on marketable equity investments.
- Margins: Gross margin expanded by 5 percentage points for the quarter and 6 percentage points for the nine-month period, attributed to a favorable product mix.
- Inventory Build: Inventory increased by $8.2M (from $15.3M to $23.4M) over the nine-month period, contributing to a negative operating cash flow of $1.5M despite strong net income.
- Debt Structure: Total notes payable increased to $18.3M from $12.0M. The company secured a new $5.0M Term Loan C and increased its revolving credit line to $11.0M in April 2025.
Guidance, Outlook, Risks, and Unusual Items
- Backlog: As of March 31, 2025, the company reported a backlog of approximately $49.5 million, with $12.8M scheduled for delivery in Q4 FY2025.
- Customer Concentration: The company relies heavily on two major customers. Customer 1 accounted for 77% of sales in the quarter and 78% for the nine-month period. Customer 2 accounted for 11%.
- Investment Activity: The company holds $5.5M in marketable equity securities. A significant portion of the current period's net income includes non-operating gains from the sale and unrealized appreciation of these securities.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective due to a material weakness regarding inventory existence controls discovered in fiscal 2024. Remediation efforts are ongoing, including the hiring of a warehouse manager.
- Risks: Risks include potential negative impacts from new U.S. tariffs on imported raw materials, the transition of a major customer's next-generation handpiece design (currently paused), and the high concentration of revenue from a single customer.
Investor Verification Checklist
- Inventory Valuation: Verify the accuracy of the $23.4M inventory balance given the disclosed material weakness in inventory existence controls.
- Customer Dependency: Assess the risk associated with Customer 1 representing 77% of quarterly revenue and the status of their next-generation product transition.
- Cash Flow Sustainability: Analyze the divergence between strong net income ($7.8M) and negative operating cash flow (-$1.5M) driven by inventory buildup.
- Debt Covenants: Review the terms of the new $11M revolving credit facility and ensure compliance with financial covenants.
- Non-Recurring Income: Evaluate the sustainability of earnings by excluding the $595k realized gain and $1.1M unrealized gain on investments.